The findings we report here, together with the nucleolin-focused independent clinical trial underway [77,78], introduce nucleolin as an attractive target for therapeutic regulation of prostate cancer, although the details of its position in cancer cell HGF signaling remain to be found. The gene discussed is HGF; the disease is prostate cancer.